Evidence map›Paper›PMID 38220239›Full record

Observational studySaudi medical journal2024

Validity of the International Diabetes Federation risk stratification score of Ramadan fasting in individuals with diabetes mellitus.

Eman M Alfadhli, Taif S Alharbi, Abrar M Alrotoie, Asia A Aljohani, Amal S Qari, Bashaer A Alsubhi, Aram H Alsaedi, Alaa A Aljohani

Open access · diamondAbstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Saudi medical journal, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
5.9field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 18 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Eman M AlfadhliFrom the Medical College (Alfadhli, Alharbi, Alrotoie, Asia Aljohani, Qari, Alsubhi, Alsaedi), Taibah University, from the Department of Internal Medicine (Alfadhli), King Faisal Specialist Hospital and Research Center, and from the Diabetes Center (Alaa Aljohani), King Salman Bin Abdulaziz Medical City, Al-Madinah Al-Munawarah, Kingdom of Saudi Arabia.ORCID https://orcid.org/0000-0003-3842-4979
Taif S AlharbiFrom the Medical College (Alfadhli, Alharbi, Alrotoie, Asia Aljohani, Qari, Alsubhi, Alsaedi), Taibah University, from the Department of Internal Medicine (Alfadhli), King Faisal Specialist Hospital and Research Center, and from the Diabetes Center (Alaa Aljohani), King Salman Bin Abdulaziz Medical City, Al-Madinah Al-Munawarah, Kingdom of Saudi Arabia.
Abrar M AlrotoieFrom the Medical College (Alfadhli, Alharbi, Alrotoie, Asia Aljohani, Qari, Alsubhi, Alsaedi), Taibah University, from the Department of Internal Medicine (Alfadhli), King Faisal Specialist Hospital and Research Center, and from the Diabetes Center (Alaa Aljohani), King Salman Bin Abdulaziz Medical City, Al-Madinah Al-Munawarah, Kingdom of Saudi Arabia.
Asia A AljohaniFrom the Medical College (Alfadhli, Alharbi, Alrotoie, Asia Aljohani, Qari, Alsubhi, Alsaedi), Taibah University, from the Department of Internal Medicine (Alfadhli), King Faisal Specialist Hospital and Research Center, and from the Diabetes Center (Alaa Aljohani), King Salman Bin Abdulaziz Medical City, Al-Madinah Al-Munawarah, Kingdom of Saudi Arabia.
Amal S QariFrom the Medical College (Alfadhli, Alharbi, Alrotoie, Asia Aljohani, Qari, Alsubhi, Alsaedi), Taibah University, from the Department of Internal Medicine (Alfadhli), King Faisal Specialist Hospital and Research Center, and from the Diabetes Center (Alaa Aljohani), King Salman Bin Abdulaziz Medical City, Al-Madinah Al-Munawarah, Kingdom of Saudi Arabia.
Bashaer A AlsubhiFrom the Medical College (Alfadhli, Alharbi, Alrotoie, Asia Aljohani, Qari, Alsubhi, Alsaedi), Taibah University, from the Department of Internal Medicine (Alfadhli), King Faisal Specialist Hospital and Research Center, and from the Diabetes Center (Alaa Aljohani), King Salman Bin Abdulaziz Medical City, Al-Madinah Al-Munawarah, Kingdom of Saudi Arabia.
Aram H AlsaediFrom the Medical College (Alfadhli, Alharbi, Alrotoie, Asia Aljohani, Qari, Alsubhi, Alsaedi), Taibah University, from the Department of Internal Medicine (Alfadhli), King Faisal Specialist Hospital and Research Center, and from the Diabetes Center (Alaa Aljohani), King Salman Bin Abdulaziz Medical City, Al-Madinah Al-Munawarah, Kingdom of Saudi Arabia.
Alaa A AljohaniFrom the Medical College (Alfadhli, Alharbi, Alrotoie, Asia Aljohani, Qari, Alsubhi, Alsaedi), Taibah University, from the Department of Internal Medicine (Alfadhli), King Faisal Specialist Hospital and Research Center, and from the Diabetes Center (Alaa Aljohani), King Salman Bin Abdulaziz Medical City, Al-Madinah Al-Munawarah, Kingdom of Saudi Arabia.
Alfaisal University · SA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesTo assess the validity of the new International Diabetes Federation-Diabetes and Ramadan International Alliance (IDF-DAR) risk stratification tool for Ramadan fasting in predicting diabetic patients' ability to fast safely.

methodsA prospective observational study was carried out during Ramadan 2022 at the Diabetes Center, King Fahad Hospital, Al-Madinah Al-Munawarah, Saudi Arabia. The IDF-DAR risk stratification tool was used to calculate fasting risk for diabetic patients pre-Ramadan. The patients were allocated into 3 categories: high, moderate, and low risk. Fasting was left up to the patients and their healthcare providers. Participants filled out a log-sheet each day of Ramadan showing whether they completed the fast. A final interview was carried out after Ramadan to assess patients' fasting experiences.

resultsWe included 466 patients with diabetes: 79.4% with T2DM and 20.6% with T1DM. Based on the IDF-DAR score, 265 (56.9%) patients were classified as high risk, 115 (24.7%) as moderate risk, and 86 (18.4%) as low risk. Non-fasting the whole month of Ramadan was statistically relevant to the IDF-DAR risk stratification score. High-risk individuals were more likely to experience hypoglycemia and hyperglycemia than those with a moderate or low risk. But overall, 70.4% of people at moderate risk and 53.2% of the ones at high risk observed Ramadan's complete fast.

conclusionThe IDF-DAR has proven to be reliable and valid for predicting the risk of adverse events associated with fasting in diabetic patients. Nonetheless, it might overestimate the risk of fasting for some patients.

Indexed as

Diabetes MellitusDiabetes Mellitus, Type 2FastingHumansHypoglycemic AgentsIslamRisk AssessmentRisk FactorsHypoglycemic Agentsdiabetes mellitusfastingIDF-DAR risk stratificationRamadanvalidity

Identifiers

PMID38220239
PMCPMC10807666
OpenAlexW4390859718

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.